1	A New Algorithm for Incidental Pancreatic Cyst Detection
2	
3	M. Álvaro Berbís ¹ , Juan Moreno-Vedia ² , Félix Paulano-Godino ¹ , Ainhoa Viteri ¹ , Meritxell
4	Riera-Marín ² , Daniel Cañadas-Gómez ² , Romina Trotta ¹ , Beatriz Forastero ¹ , Luis Luna ¹ ,
5	Javier García López ² , Antonio Luna ³ , Júlia Rodríguez-Comas ²
6	
7	¹ Department of Radiology, HT Médica, San Juan de Dios Hospital, 14012 Córdoba, Spain.
8	² Scientific and Technical department, Sycai Technologies S.L., 08018 Barcelona, Spain.
9	³ Department of Radiology, HT Médica, Clínica las Nieves, 23007, Jaén, Spain
10	
11	
12	Corresponding author:
13	M. Álvaro Berbís, PhD
14	Radiology Department, HT Médica, Hospital San Juan de Dios de Córdoba
15	Avda. Brillante 106, 14012 Córdoba, Spain
16	a.berbis@htime.org
17	
18	

19 ABSTRACT

Objectives: To develop an accurate, state-of-the-art algorithm for the incidental detection of
 pancreatic cystic lesions (PCLs) on computerized tomography (CT) and magnetic resonance
 imaging (MRI) scans.

Methods: A SwinT-Unet-based architecture was developed for the incidental detection of
PCLs. The algorithm was trained and validated on a robust dataset of retrospective CT and
MRI studies collected from HT Médica centers located in eight different cities using scanners
fabricated by four different manufacturers.

Results: Our algorithm was able to detect 91.6% of the confirmed PCLs in the initial dataset with 91.6% sensitivity and 92.3% specificity, while 91.7% of the healthy controls were also correctly identified. Furthermore, our tool was remarkably capable of classifying these PCLs as mucinous or non-mucinous, determining their location within the pancreas with an accuracy of 88.5%, and identifying the presence of calcifications or scars within the PCLs with an accuracy of 96%.

33 **Conclusions:** By integrating radiological data and state-of-the-art artificial intelligence 34 techniques, we have developed an efficient tool for the incidental identification and initial 35 characterization of PCLs, which present a substantial prevalence within the global 36 population. Our algorithm facilitates early diagnosis of pancreatic abnormalities, which could 37 have a profound impact on patient management and prognosis, particularly in the case of 38 PCLs with malignant potential.

- 40 Keywords: Pancreatic Cysts, Computerized Tomography, Magnetic Resonance Imaging,
- 41 Incidental Findings, Artificial Intelligence, SwinT-Unet.

43 INTRODUCTION

Pancreatic cancer (PC) currently ranks as the twelfth most common type of cancer globally [1], and it is further expected to become the second leading cause of cancer-related mortality by 2030 [2]. Moreover, PC is one of the most lethal types of cancer, with a 5-year survival rate inferior to 10% [3]. The delayed onset of PC symptoms, often appearing when metastasis has already occurred, results in up to 85% of patients no longer being eligible for surgical resection, which has a profound negative impact on their prognosis [4,5].

Many research efforts are currently focused on the identification of biomarkers for early PC 50 detection, aiming to improve patient outcomes. However, only one of these biomarkers, the 51 serum carbohydrate antigen 19-9, has been approved by the US Food and Drug 52 Administration (FDA), and only as a therapy response and disease relapse monitoring 53 54 marker, as its predictive value is too low for population screening purposes [6]. Nonetheless, there is an opportunity for early PC diagnosis in patients presenting pancreatic cystic lesions 55 (PCLs), as some of them are well-known precursors for this malignancy. The widespread 56 adoption of advanced imaging techniques, particularly computed tomography (CT) and 57 magnetic resonance imaging (MRI), has led to an increased identification of conditions 58 unrelated to the initially suspected diagnosis. These incidental findings can indeed be 59 fortunate discoveries when they entail the early detection of a potentially treatable 60 malignancy. Unsuspected PCLs have a prevalence of 2.6% in CT scans [7] and of 13.5-61 19.6% in MRI studies [8,9], and both show a strong correlation with advanced age. 62 Unexpectedly, a recent study found a much higher prevalence (49.1%) of incidental PCLs in 63 healthy individuals, which also increased with body mass index and age [10]. 64

65 PCLs can have a non-neoplastic (pseudocysts) or a neoplastic nature. Among the latter, 66 serous cystadenomas (SCA) are typically regarded as benign [11], while mucinous cysts are 67 often associated with malignant potential. Intraductal papillary mucinous neoplasms (IPMN) 68 and mucinous cystic neoplasms (MCN) are two well-known PC precursors. IPMNs can arise from the side branches, the main pancreatic duct, or a combination of both, with a notably 69 70 higher prevalence of PC found in main duct IPMNs [12]. Thus, this distinction has a direct 71 impact on patient management and prognosis. PC cases arising from PCLs have been 72 proposed to follow a systematic model in which malignancy progression occurs over several 73 years, thus offering an opportunity for early diagnosis [13,14]. However, differentiation 74 between the different types of PCLs is challenging, and although the presence of some 75 specific features can be indicative of malignancy [15,16], these signs are sometimes not 76 enough to confidently distinguish between benign and malignant PC precursors. Nevertheless, early detection of PCLs is essential to improve patient outcomes and reduce 77 78 the economic strain on healthcare systems, as it would allow more informed, enhanced 79 decision-making regarding lesion management and monitoring, thus potentially preventing progression to PC. 80

Artificial intelligence (AI) tools are poised to play a crucial role in the early detection of PCLs in CT and MR images. These algorithms have the potential to accurately identify and define lesion boundaries and to extract essential qualitative and quantitative information from their features, thus improving diagnostic precision. The implementation of these tools would also help to streamline the workflow in radiology departments, providing valuable assistance to radiologists in the diagnostic process and reducing their workload. The capability of convolutional neural networks (CNNs) to learn the spatial hierarchies of features from input

88 data in an automatic and adaptive manner makes them exceptionally useful for extracting 89 information from medical images. This capability allows CNNs to learn complex patterns at different levels of abstraction, recognize patterns independently of their spatial location, and 90 even identify new patterns not obvious to the human eve. Moreover, depending on the 91 92 specific dataset they are trained on, CNNs can work with multiple types of imaging studies (ultrasound, CT, MRI, etc.) and perform a wide variety of tasks (detection, segmentation, 93 classification, etc.). Applied to medical images, the AI model presented in this manuscript, 94 based on the SwinT-Unet architecture, offers exceptional segmentation accuracy and 95 remarkable generalization ability, allowing the discrimination of structures at the pixel level. 96 97 The results showed an outstanding performance of our algorithm, achieving 91.6% sensitivity and 92.3% specificity in the incidental detection of PCLs, while also 98 demonstrating a remarkable capacity to further characterize the lesion by classifying it as 99 mucinous or non-mucinous, accurately determining its location within the pancreas, and 100 identifying the presence of calcifications or scars within the PCLs. Our findings confirm a 101 significant prevalence of PCLs within our study population, highlighting the crucial support 102 a tool like ours might provide through the early diagnosis of pancreatic abnormalities and the 103 significant impact this would have on patient management and prognosis, particularly in the 104 105 case of PLCs with malignant potential.

106

107 MATERIALS AND METHODS

108 Patients

The total cohort included 43.3% women (**table 1**). This initial cohort was divided into two subgroups: the control group included 56.3% of the patients (37.9% women, **table 2**), while the second group, comprising patients who had been diagnosed with a PCL, included 43.7% of the study population (**table 3**). Both groups showed a similar age distribution, and women and men were equally represented in the PCL group, which was further characterized to analyze the performance of our algorithm.

115

116 Imaging

Image studies were acquired at different HT Médica medical centers located in the Spanish cities of Jaén, Córdoba, El Ejido, Huelva, Cádiz, Jerez de la Frontera, Algeciras, and Sevilla, from January 2018 to December 2021, using scanners developed by the following manufacturers (tables 1–3): Canon Medical Systems (Otawara, Japan), GE Healthcare (Chicago, IL, United States), Philips (Amsterdam, The Netherlands), and Siemens Healthineers (Erlangen, Germany). Demographic data of the patients, including age and gender, were collected from HT Médica's radiological information system.

124

125 Segmentation and feature extraction

A team of radiologists, each of them with more than five years of experience, manually delineated the pancreas and PCLs in all the images, slice by slice, using the 3D modeling tool available in the Philips IntelliSpace Portal (v12.1). The segmentations were subsequently exported in RTSTRUCT format. To ensure agreement between raters, collaborative

segmentation, and consensus resolution were employed, minimizing discrepancies in theassessment process.

132

133 *Algorithm development*

The proposed model (fig1) is based on the SwinT-Unet [17] architecture, a further 134 development from the U-Net [18] that aims to predict objects on an image with pixel-wise 135 accuracy. Our model includes an encoder block, to reduce input resolution, and a U-Net 136 decoder with dual-scale information modules. The encoder is an attention-based model with 137 138 blocks that capture information at multiple scales, similar to that proposed by Atek et al. [17]. The input image is processed through multiple Swin transformer blocks performing attention 139 140 operations and feature transformation. These blocks are responsible for feature extraction at various scales, allowing the model to capture both the fine details and high-level abstract 141 features. After information passes through the encoder, the architecture adopts a U-Net-like 142 143 structure [18] to perform segmentation. The decoder takes the features extracted by the 144 encoder and uses them to generate a segmentation mask of the same resolution as the original 145 input. Additionally, the decoder incorporates dual-scale information modules to merge 146 features from different resolution levels that allow the model to integrate detailed and 147 contextual information at different scales, thus improving segmentation accuracy, especially 148 in areas with fine details or small features. This ability to process features and key points at 149 different levels is crucial for the network to learn the features that best characterize big organs, such as the liver, as well as small lesions with different shapes and textures, such as 150 151 PCLs. The network was specifically trained to learn the position and shape of the liver, kidneys, and pancreas, as well as a wide range of benign, pre-malignant, and malignant 152

lesions present in the training set corresponding to the aforementioned organs. The model proposed here further includes two more steps: (1) a pre-processing step, prior to the inference of the neural network, that normalizes the input image by applying a Soft-Tissue Normalization [19], and (2) a post-processing step after the inference the filters out potential detections of the network that have no anatomical meaning, such as lesions belonging to an organ which they are not in direct contact with or predictions present in parts of the study where the abdomen is not visible yet.

160

161 *Statistical analysis*

162 The Kolmogorov–Smirnov test was used to assess normality. Categorical variables are 163 presented as total numbers and percentages, and continuous variables are presented as 164 medians and interquartile ranges (IQRs) for non-normally distributed data. The chi-square 165 (χ 2) test was used to analyze group differences for categorical variables, while the Mann– 166 Whitney U test was used for continuous variables. Results were considered statistically 167 significant if *p*<0.05. Statistical analyses were conducted using the SPSS Statistics, version 168 29.0.0.0 (IBM, Armonk, NY, United States).

169

170 **RESULTS**

171 *Patient's characteristics*

The median age of the patients included in the present study was 66 years old. The 61–80 age range was the most represented, consistent with the expected increase in CT and MRI scans performed as the population ages. Women accounted for 43.3% of the initially

evaluated patients (table 1). The recruited cohort was divided into two groups: one group
with confirmed PCLs, including 43.7% of the patients, and a control group of healthy
individuals. Both groups showed a similar age distribution, and women and men were equally
represented in the PCL group (tables 2 and 3).

Among these PCL lesions, 61.1% of them were identified as non-mucinous (serous cystic 179 neoplasms (SCN), pseudocysts) and 38.9% were classified as mucinous (MCNs, IPMNs). 180 Within the non-mucinous group, 93.8% of them were SCNs or pseudocysts; additionally, 181 182 3.8% of non-subclassified benign lesions and 2.5% of undetermined non-mucinous lesions 183 were detected (table 4). The prevalence of both mucinous and non-mucinous lesions 184 increased with age, with mucinous cases associated with a higher median age (p < 0.001). 185 Notably, a higher percentage of patients with mucinous lesions fell within the 61-80 age 186 range, consistent with the expectation of a higher lesion incidence in older patients [10].

187

188 Incidental finding of PCLs

Out of the initial dataset, 43.7% of the cases were confirmed as true positives for a PCL, based on radiological evidence. This prevalence is in alignment with the existing literature, which reports the presence of PCLs in up to 49.1% of the adult population [10]. Our algorithm successfully detected 91.6% of the lesions, while 8.4% were missed (false negatives). Furthermore, among the control population, the algorithm accurately identified a healthy pancreas in 91.7% of the cases but presented 7.7% of false positives.

195 Overall, our SwinT-Unet-based model showed 91.6% sensitivity and 92.3% specificity in the

detection of PCLs. These results confirm the high precision and reliability of our AI-based

approach in distinguishing between cystic lesions and non-cystic structures within the
pancreas, underscoring the potential of AI technology to enhance the accuracy and efficiency
of pancreatic lesion detection, thereby facilitating early diagnosis and treatment planning for
patients with pancreatic abnormalities.

201

202 Characterization of PCLs: mucinous vs. non-mucinous classification and location

203 While the majority of pancreatic cysts carry a low risk of malignancy, some are recognized 204 as premalignant lesions capable of progressing into mucin-producing adenocarcinoma. 205 Consequently, the identification of these cysts often triggers heightened anxiety in the patient and prompts additional medical investigations to assess the potential for malignancy [20,21]. 206 While the primary objective in this study was the incidental detection of PCLs, the 207 208 classification of these cysts as mucinous (IPMNs, MCNs) or non-mucinous (SCNs, pseudocysts) [22] was also addressed, achieving an accuracy of 73.3% in the classification 209 210 of PLCs as mucinous (fig2).

Furthermore, we analyzed the spatial distribution of the PCLs within the pancreas, with the algorithm demonstrating a high accuracy (88.5%) in categorizing the cysts as head, body, or tail, according to their location. Specifically, the algorithm was capable of correctly determining the location of the lesion at the head or the uncinate process of the pancreas with an accuracy of 86%, at the body with an accuracy of 92.6%, and at the tail with an accuracy of 75.7%.

Additionally, we conducted a thorough examination for the presence of calcifications or scars
within the cystic lesions, achieving an accuracy of 96% in their identification. This was

crucial to assess the presence of potential signs of malignancy or chronic inflammation within 219 the PCL. To achieve this, several image feature extraction algorithms were applied to study 220 the high increments of Hounsfield Units (HU) on small sliding windows passed through 221 222 patches of the image where the lesion was detected. A map of the increased direction of the 223 HU within the sliding window is thus generated and, by calculating its maximum, the candidates to potential scars (understood as groups of pixels with a high HU, since they have 224 225 a great bone component that is aligned towards a defined direction within the PCL) are 226 extracted.

This comprehensive characterization of the PCL provides valuable insights into the diverse
nature of the lesion, supporting clinicians in diagnostic decision-making and risk
stratification for further management strategies.

230

231 **DISCUSSION**

Considerable efforts have been employed to try to distinguish between the different types of 232 PCLs, as this step is essential to correctly stratify the malignant potential of the lesion so the 233 234 best patient management can be provided. Duh et al. developed an AG-Net model capable of 235 identifying PCLs on CT scans with 93.1% sensitivity and 81.8% specificity, further classifying them into two groups (IPMN and MCN vs pseudocysts and SCAs) [23]. Vilas-236 237 Boas et al. designed a CNN for the automatic detection of mucinous PCLs. The algorithm, trained on images retrieved from EUS examination videos, achieved 98.5% accuracy, 98.3% 238 sensitivity, and 98.9% specificity in the classification of PCLs as mucinous or non-mucinous 239 240 [24]. Yang et al. developed a random forest (RF) model capable of differentiating between

241 serous and mucinous pancreatic cystadenomas based on the analysis of radiomics texture 242 features extracted from CT scans. Their algorithm achieved 0.83 accuracy, 0.85 sensitivity, and 0.83 specificity for a slice thickness of 5 mm [25]. Shen et al. compared the performance 243 of a support vector machine (SVM) model, an RF algorithm, and an artificial neural network 244 245 (ANN) in differentiating among SCAs, MCNs, and IPMNs using eight clinical factors and 246 nine radiomics features extracted from CT scans [26]. The RF classifier offered the best 247 results, achieving an accuracy of 79.59% and F1 scores of 0.7500 for the differentiation of IPMNs, 0.8182 for MCNs, and 0.8077 for SCAs. Gao et al. designed a CNN to identify 248 pancreatic anomalies, including PCLs, on MRI images [27]. The authors employed 504 249 250 original pre-treatment MRI studies to train their model. As most of the patches within the images corresponded to carcinoma, they augmented the number of images for the other 251 252 conditions with the help of a generative adversarial network (GAN), creating synthetic images based on real ones up to a total of 35735 patches for the training dataset. The CNN 253 trained on this augmented dataset offered its best results when a synthetic to real images ratio 254 of 40:1 was used, achieving an AUC of 0.9147 for the identification of carcinomas, 0.8486 255 for benign ductal diseases, 0.9126 for benign cystic diseases, 0.7189 for inflammatory 256 diseases, 0.9301 for pancreatic neuroendocrine tumors, and 0.8880 for solid pseudopapillary 257 258 tumors.

The number of studies exploring the incidental finding of PCLs via AI approaches is much reduced. Kooragayala et al. employed a publicly available natural language processing (NLP) software to identify incidental findings on CT scan reports [28]. The authors created a list of specific terms (including IPMN, pancreatic cyst, and pancreatic ductal dilation) to identify pancreatic findings that were used as parameters to train the algorithm on a subset of 28

patients who had undergone pancreatic resection for known pancreatic lesions. This algorithm achieved an accuracy of 0.987 on a validation set of 400 CT scan reports. Their optimized model was subsequently applied to 18769 CT studies from patients admitted at their institution for trauma and findings of interest were identified in 232 of them, including potential IMPNs (48 patients), pancreatic cysts (36 patients), concerning masses (30 patients), traumatic findings (44 patients), pancreatitis (41 patients), and ductal abnormalities (19 patients).

By utilizing CT and MRI scans originally intended for the identification or evaluation of 271 272 conditions not related to pancreatic abnormalities, the algorithm we present in this study offers a novel approach to the detection of PCLs. Our tool confirmed the incidental presence 273 274 of PCLs in 43.7% of the study population, in accordance with previously reported data [10]. 275 Out of all confirmed cases, the SwinT-Unet-based algorithm correctly identified 91.6% of 276 them with a remarkable 91.6% sensitivity and 92.3% specificity, improving the results 277 reported by Duh et al., which were obtained with an algorithm specifically designed for the 278 classification of PCLs, not for their incidental detection. Furthermore, our algorithm is capable of providing a comprehensive characterization of the PCL through its classification 279 as mucinous or non-mucinous with 73.3% accuracy. Although this result did not improve 280 281 those previously reported [24-27], the tool presented here can further characterize the PCL by categorizing the lesion according to its location in the head, body, or tail of the pancreas 282 with 88.5% accuracy, as well as identifying the presence of calcifications or scars within the 283 284 PCL with 96% accuracy. Taken together, all this information provides a comprehensive characterization of the lesion that, without any doubt, will be very valuable to clinicians for 285 286 the planning of tailored patient management strategies.

The results presented in this study were achieved using a robust dataset consisting of CT and MRI studies obtained from eight different medical centers using scanners fabricated by four different manufacturers. However, they are limited by the somewhat reduced number of imaging studies included.

291

292 CONCLUSIONS

Our study presents comprehensive findings regarding the incidental detection and characterization of PCLs through the integration of radiological data and advanced AI techniques. The results reveal a substantial prevalence of PCLs within the studied population,

highlighting the importance of thorough radiological evaluations in clinical practice.

297 Our AI model, based on the SwinT-Unet architecture, showed a remarkable performance in detecting PCLs with a sensitivity of 91.6% and a specificity of 92.3%. Furthermore, our study 298 299 contributes to the in-depth characterization of PCLs by distinguishing between mucinous and non-mucinous types, aiding in risk stratification and clinical decision-making, and the 300 301 identification of calcifications or scars within the cystic lesions, an aspect crucial for the 302 assessment of potential signs of malignancy or chronic inflammation within the PCL. These outcomes not only emphasize the clinical utility of our approach but also highlight the 303 304 potential of AI-driven approaches in enhancing the accuracy and efficiency of pancreatic 305 lesion detection, which will undoubtedly have a profound impact on patient management and 306 prognosis, particularly in the case of PCLs with malignant potential.

307

309 DECLARATIONS

310 Funding

311	This project was co-financed by the European Union (NextGenerationEU) through the Public
312	Business Entity Red.es, affiliated to the Secretaría de Estado de Digitalización e Inteligencia
313	Artificial, Ministerio de Asuntos Económicos y Transformación Digital (Secretary of State
314	for Digitalization and Artificial Intelligence, Ministry of Economic Affairs and Digital
315	Transformation) within the framework of the 2021 Call for Aid for research and development
316	projects in artificial intelligence and other digital technologies and their integration into value
317	chains (C005/21-ED call, project reference 2021/C005/00153960).

318

319 Competing interests

M. Álvaro Berbís is the CEO of Cells IA Technologies. Antonio Luna received institutional royalties and institutional payments for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Canon, Bracco, Siemens Healthineers, and Philips Healthcare and is a board member of Cells IA Technologies. Júlia Rodríguez-Comas is the CTO of Sycai Technologies. The remaining authors have no competing interests to declare that are relevant to the content of this article.

326

327 Ethics approval

328	This research was performed in accordance with the ethical standards in the 1964 Declaration
329	of Helsinki. The protocol followed in this study was approved by the Institutional Review
330	Board of HT Médica.
331	
332	Consent
333	Written informed consent was obtained from the patients at the time of the performance of
334	the imaging study.
335	
336	Data, Materials, and/or Code availability
337	The data used in this study are not openly available due to commercial and proprietary
338	constraints. Access to the data may be granted by the corresponding author upon reasonable
339	request and subject to confidentiality agreements.
340	
341	Authors' contributions
342	Study conception and design were performed by M. Álvaro Berbís and Júlia Rodríguez-
343	Comas. Material preparation, data collection, and analysis were performed by M. Álvaro
344	Berbís, Juan Moreno-Vedia, Félix Paulano-Godino, Ainhoa Viteri, Meritxell Riera-Marín,
345	Daniel Cañadas-Gómez, Romina Trotta, Beatriz Forastero, Luis Luna, and Javier García
346	López. Supervision was performed by M. Álvaro Berbís and Júlia Rodríguez-Comas. The
347	first draft of the manuscript was written by M. Álvaro Berbís, Javier García López and Júlia
348	Rodríguez-Comas. Manuscript review and editing was performed by Antonio Luna. All

- 349 authors commented on previous versions of the manuscript. All authors read and approved
- the final manuscript.

352 **REFERENCES**

- 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer
- Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
 Countries. CA Cancer J Clin. 2021;71:209–49.
- 2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer
- Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in
 the United States. Cancer Res. 2014;74:2913–21.
- 359 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
- 4. Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal
 adenocarcinoma based on real-world data. Sci Rep. 2020;10:16425.
- 362 5. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. The Lancet.
 363 2011;378:607–20.
- 6. Kim J, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9
 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol.
 2004;19:182–6.
- 7. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, et al. Prevalence of
 Unsuspected Pancreatic Cysts on MDCT. American Journal of Roentgenology. 2008;191:802–7.
- 369 8. Zhang X-M, Mitchell DG, Dohke M, Holland GA, Parker L. Pancreatic Cysts: Depiction on Single370 Shot Fast Spin-Echo MR Images. Radiology. 2002;223:547–53.
- 9. Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of Incidental Pancreatic Cysts in the Adult
 Population on MR Imaging. American Journal of Gastroenterology. 2010;105:2079–84.
- 10. Kromrey M-L, Bülow R, Hübner J, Paperlein C, Lerch MM, Ittermann T, et al. Prospective study
 on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a
 population-based study. Gut. 2018;67:138–45.
- 11. Jais B, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L, et al. Serous cystic neoplasm of
- the pancreas: a multinational study of 2622 patients under the auspices of the International
- Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic
- 379 Tumors of the Pancreas). Gut. 2016;65:305–12.
- 380 12. Tanaka M, Chari S, Adsay V, Carlos Castillo F-D, Falconi M, Shimizu M, et al. International
- 381 Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and
- 382 Mucinous Cystic Neoplasms of the Pancreas. Pancreatology. 2006;6:17–32.
- 13. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al.
- Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic
 Intraepithelial Neoplasia Tissue Microarray. Modern Pathology. 2003;16:902–12.
- 14. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the
 genetic evolution of pancreatic cancer. Nature. 2010;467:1114–7.

15. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789–804.

16. Tanaka M, Fernández-del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of

international consensus Fukuoka guidelines for the management of IPMN of the pancreas.

391 Pancreatology. 2017;17:738–53.

- 17. Atek S, Mehidi I, Jabri D, Belkhiat DEC. SwinT-Unet: Hybrid architecture for Medical Image
- 393 Segmentation Based on Swin transformer block and Dual-Scale Information. 2022 7th International
- Conference on Image and Signal Processing and their Applications (ISPA). IEEE; 2022. p. 1–6.
- 18. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image
- Segmentation. In: Navab N, Hornegger J, Wells WFA, editors. Medical Image Computing and
 Computer-Assisted Intervention MICCAI 2015 MICCAI 2015 Lecture Notes in Computer Science().
 2015. p. 234–41.
- 19. Huo Y, Tang Y, Chen Y, Gao D, Han S, Bao S, et al. Stochastic tissue window normalization of
 deep learning on computed tomography. Journal of Medical Imaging. 2019;6:1.
- 401 20. Polk SL, Choi JW, McGettigan MJ, Rose T, Ahmed A, Kim J, et al. Multiphase computed
- 402 tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict
 403 malignancy. World J Gastroenterol. 2020;26:3458–71.
- 404 21. Anand N, Sampath K, Wu BU. Cyst features and risk of malignancy in intraductal papillary
 405 mucinous neoplasms of the pancreas: A meta-analysis. Clinical Gastroenterology and Hepatology.
- 406 2013;11:913–21.
- 407 22. Udare A, Agarwal M, Alabousi M, McInnes M, Rubino JG, Marcaccio M, et al. Differentiation of
 408 Benign and Malignant Pancreatic Cystic Lesions Compared to CT and Endoscopic Ultrasound:
 409 Systematic Review and Meta-analysis. J Magn Reson. 2021;
- 410 23. Duh MM, Torra-Ferrer N, Riera-Marín M, Cumelles D, Rodríguez-Comas J, García López J, et al.
- 411 Deep Learning to Detect Pancreatic Cystic Lesions on Abdominal Computed Tomography Scans:
 412 Development and Validation Study. JMIR AI. 2023;2:e40702.
- 24. Vilas-Boas F, Ribeiro T, Afonso J, Cardoso H, Lopes S, Moutinho-Ribeiro P, et al. Deep Learning
 for Automatic Differentiation of Mucinous versus Non-Mucinous Pancreatic Cystic Lesions: A Pilot
 Study. Diagnostics. 2022;12:2041.
- 416 25. Yang J, Guo X, Ou X, Zhang W, Ma X. Discrimination of Pancreatic Serous Cystadenomas From
 417 Mucinous Cystadenomas With CT Textural Features: Based on Machine Learning. Front Oncol.
 418 2019;9.
- 26. Shen X, Yang F, Yang P, Yang M, Xu L, Zhuo J, et al. A Contrast-Enhanced Computed Tomography
 Based Radiomics Approach for Preoperative Differentiation of Pancreatic Cystic Neoplasm
- 421 Subtypes: A Feasibility Study. Front Oncol. 2020;10.
- 422 27. Gao X, Wang X. Performance of deep learning for differentiating pancreatic diseases on
- 423 contrast-enhanced magnetic resonance imaging: A preliminary study. Diagn Interv Imaging.
- 424 2020;101:91–100.

- 425 28. Kooragayala K, Crudeli C, Kalola A, Bhat V, Lou J, Sensenig R, et al. Utilization of Natural
- 426 Language Processing Software to Identify Worrisome Pancreatic Lesions. Ann Surg Oncol.
- 427 2022;29:8513–9.

428

430 FIGURES



431



434 connected by two successive Swin transformer blocks (bottleneck).

435



438 Fig2. Original images and predictions made by our algorithm. (A) Mucinous PCL. (B)

439 Non-mucinous PCL. Healthy pancreas is shown in purple, while the lesions appear in yellow.

440

442 TABLES

	Total Cases	р
Age (years)	66 (55-74)	
0-18	0	<0.001
19-40	3.7%	
41-60	32%	
61-80	60%	
81-100	4.3%	
Women	43.3%	0.021
Manufacturer		<0.001
Siemens	47%	
Philips	26.3%	
GE Medical systems	15.7%	
Canon Medical Systems	11%	

443 Table 1. Demographic and manufacturer distribution of the total cases included in the study.

444

446	Table 2. Demographic and manufacture	r distribution of the control	cases included in the study.
-----	--------------------------------------	-------------------------------	------------------------------

	Control Cases	р
Age (years)	65 (56-72)	
0-18	0	<0,001
19-40	4.1 %	
41-60	32%	
61-80	61.2%	
81-100	1.8%	
Women	37.9%	0.002
Manufacturer		<0,001
Siemens	40.8%	
Philips	27.8%	
GE Medical systems	16%	
Canon Medical Systems	15.4%	

	PCL Cases	р
Age (years)	68 (54-76)	
0-18	0	<0.001
19-40	3.1%	
41-60	32.1%	
61-80	57.3%	
81-100	7.6%	
Women	50.4%	0.930
Manufacturer		<0.001
Siemens	55%	
Philips	24.4%	
GE Medical systems	15.3%	
Canon Medical Systems	5.3%	

454 Table 3. Demographic and manufacturer distribution of the PCL cases included in the study.

455 PCL: Pancreatic Cystic Lesion

	Mucinous PCL	Non-mucinous PCL	р
SCN	-	70%	
Pseudocyst	-	23.8%	
Benign non-subclassifiable	-	3.8%	
Undetermined	-	2.5%	
IPMN	90.2%	-	
MCN	9.8%	-	
Age (years)	72 (64-79)	63 (51-74)	<0.001
0-18	0	0	
19-40	0	5%	
41-60	19.6%	40%	
61-80	68.6%	50%	
81-100	11.8%	5%	
Women	54.9%	47.5%	0.409

Table 4. Clinical and demographic characteristics of mucinous and non-mucinous PCLs.

PCL: Pancreatic Cystic Lesion; SCN: Serous Cystic Neoplasms; IPMN: Intraductal Papillary Mucinous

Neoplasms; MCN: Mucinous Cystic Neoplasms.